NCT05080790View on ClinicalTrials.gov

Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 15, 2021

Primary Completion Date

January 20, 2025

Study Completion Date

January 20, 2025

Conditions

Leiomyosarcoma

Interventions

DRUG

Dinutuximab Beta, Zoledronic acid, Interleukin-2

Five 5-week cycles (Q5W) of dinutuximab beta, zoledronic acid and low-dose interleukin (IL-2)

Trial Locations (2)

13125

Helios Klinikum Berlin-Buch, Berlin

15526

HELIOS Klinikum Bad Saarow, Bad Saarow

All Listed Sponsors

collaborator

RECORDATI GROUP

INDUSTRY

lead

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

OTHER

NCT05080790 - Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma | Biotech Hunter | Biotech Hunter